AMG 986

Drug Profile

AMG 986

Alternative Names: AMG986

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Heart failure therapies; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 12 Mar 2018 Amgen completes a phase I trial for Heart failure (In volunteers, In patients with severely impaired renal function) in USA (PO) (NCT03318809)
  • 12 Dec 2017 Amgen initiates enrolment in a phase I trial for Heart failure (In volunteers, In patients with severely impaired renal function) in USA (PO) (NCT03318809)
  • 27 Oct 2017 Amgen plans a phase I trial for Heart failure (In volunteers, In patients with severely impaired renal function) in USA (PO) in November 2017 (NCT03318809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top